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Cell death plays an important role in the regulation of inflammation and may be the result of inflammation.
The maintenance of tissue homeostasis necessitates both the recognition and removal of invading microbial
pathogens as well as the clearance of dying cells. In the past few decades, emerging knowledge on cell death
and inflammation has enriched our molecular understanding of the signaling pathways that mediate various
programs of cell death and multiple types of inflammatory responses. This review provides an overview of the
major types of cell death related to inflammation. Modification of cell death pathways is likely to be a logical
therapeutic target for inflammatory diseases.
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One of the most important factors in the development
and homeostasis of organisms is the balance between
cell survival and cell death. Early in 1960, apoptosis
was considered the only standard programmed cell
death form [1, 2], whereas necrosis was mostly
considered an ‘accidental’ cell death that occurred in
response to physical and chemical insults. Following
the progression in cell death research, a tight link was
demonstrated between molecularly defined cell death
and inflammation. In host defense, programmed cell
death can act in a protective manner; the death of in-
fected cells may reduce microbial infections, separate
uninfected neighboring cells, and alert the host
through danger signals and inflammatory mediators.
This review depicts intimate interconnections between
cell death and inflammation and the pivotal protein in
each special mechanistic module that executes the
process of cell death and inflammation.* Correspondence: jif7@pitt.edu
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Necrosis, necroptosis, and inflammation
Traditionally, necrosis is considered the primary form
of cell death caused by inflammation. Necrosis was his-
torically viewed as an accidental subroutine, largely
resulting from very harsh physicochemical stimuli,
including abrupt changes in temperature, osmotic
pressure, or pH. Necrosis is morphologically identified
by the swelling of organelles, increased cell volume,
disruption of the plasma membrane, and loss of intra-
cellular content. Necrosis is recognized as a cause of
inflammation; the release of intracellular materials,
which are termed as damage-associated molecular
patterns (DAMPs), can trigger inflammatory reactions.
DAMPs are the key to the pathogenesis of sterile in-
flammation, including gout, atherosclerosis, ischemia-
reperfusion, and Alzheimer’s disease. For example, the
DAMP molecule high-mobility group box 1 (HMGB1)
can be released from necrotic cells and, in turn, stimulates
neighboring cells via the receptor for advanced-glycation
end-products (RAGE) to express proinflammatory cyto-
kines, chemokines, and adhesion molecules, therefore
inducing inflammation [3]. Recent studies using genetic
approaches [4–7] and chemical inhibitors of necrosis [4, 8,
9] demonstrated the existence of multiple pathways of
regulated necrosis.
Among the pathways of regulated necrosis, necrop-
tosis is currently most frequently mentioned andhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Fig. 1 Model of TNF receptor signaling regulation of cell fate. Upon the binding of TNF to its receptor TNFR1, RIP1 is recruited to TNFR1 and is
subsequently ubiquitinated. The polyubiquitinated RIP1, in turn, binds to NEMO, the regulatory subunit of NF-kB, to promote NF-κB activation, which
leads to the induction of pro-survival genes to counter the death signals. Cell survival is a result of this pathway. The polyubiquitinated RIP1 can also
migrate to the cytoplasm, where RIP1 is de-ubiquitinated by A20, the de-ubiquitylating enzyme. RIP1 and RIP3 can then form a pro-necrotic complex
followed by phosphorylation on both kinases and induction of necroptosis. In circumstances in which caspase-8 is activated, RIP1 and RIP3 can be
cleaved by caspase-8, and the pro-necrotic complex is blunted, which stimulates the cell to undergo apoptosis
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death mediated through a pathway that depends on
the receptor-interacting protein kinase (RIP)1-RIP3
complex and that can be inhibited by Necrostatin-1
(Nec-1) [10] (Fig. 1). Necroptosis is induced by a class
of death receptors that includes tumor necrosis factor
receptor (TNFR)1, TNFR2, and Fas. Of these, the
TNF-α/TNFR-induced pathway is the most widely
studied. Binding of TNF-α to the extracellular portion
of TNFR1 causes allosteric changes in the intracellular
portion of TNFR1 followed by the release of the
silencer of death domains (SODD) from the intracellu-
lar domain of TNFR1 [11]. TNFR1 and TNFR2 form
complex I containing a death domain (e.g., TNF-α
receptor-associated death domain (TRADD)), RIP1,
Fas-associated death domain (FADD), and several E3
ubiquitin ligases, such as TNF-α receptor associated
factor 2/5 (TRAF2/5) and inhibitor of apoptosis pro-
teins (IAPs) cIAP1 and cIAP2 [12]. RIP1 is initially
recruited to complex I and is polyubiquitinated by
TRAF2/5, cIAP1, and cIAP2 [13, 14]. Because RIP1
exhibits a biphasic effect based on its ubiquitination
state, complex I is situated at the crossroads of cell
survival and death. Deubiquitination of RIP1 can
inhibit the NF-κB pathway, which promotes cell deathpathways. Whether TRADD is required for necropto-
sis potentially depends upon the type of stimulus.
TNFR1 activation together with the absence of c-IAPs
(IAP antagonist treatment), translation inhibition
(cyclohexamide treatment), or RIP1 deubiquitination
by the deubiquitinating enzyme (DUB) CYLD may
promote the translocation of RIP1 to a secondary
cytoplasmatic complex, Complex II [15–17]. Complex
II is formed by the death domain containing protein
FADD, caspase-8 and cFLIP. Complex II may activate
either apoptotic or necroptotic downstream signaling
pathways. Activation of caspase-8 drives complex II
into a pro-apoptosis state by cleaving RIP1 and RIP3.
However, when the apoptosis pathway is inhibited, a
complex named the “necrosome” is formed (Fig. 1).
The necrosome is primarily composed of RIP1 and
RIP3 and distinctly enhances necroptosis [18].
The pseudokinase MLKL is a substrate of RIP3
required for necroptosis [4, 19]. Unlike its previous dis-
covered function in regulating mitochondrial fission,
MLKL recruitment and phosphorylation caused by
RHIM-dependent oligomerization and intramolecular
RIP3 autophosphorylation [20, 21] results in an activated
state able to induce necroptosis [22]. Furthermore,
several studies have deciphered a role for MLKL in
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plasma membrane localization is associated with its cyto-
toxicity [23–26]. MLKL binds to phosphatidylinositol
phosphates (PIPs) [23, 25] and subsequently modifies
sodium or calcium influx through ion channels, thereby
increasing osmotic pressure and promoting plasma mem-
brane rupture [24, 26, 27].
The mechanism by which the necrosome causes cell
death remains unclear. Necroptosis shares some identi-
cal sub-cellular events with necrosis, such as oxidative
burst, mitochondrial membrane hyperpolarization, lyso-
somal membrane permeabilization, and plasma membrane
permeabilization. However, the mechanisms underlying
those processes might be different [28]. Reactive oxygen
species (ROS) potentially lead to cell death by directly oxi-
dizing or triggering various downstream pathways in the
mitochondria [29–31]. RIP3 accelerates mitochondrial ROS
production and mitochondrial metabolism through the
activation of a series of metabolism-related enzymes,
including NADPH and JNK [32, 33]. Mitochondria also
contribute to necrotic cell death through an ADP/ATP-re-
lated pathway in addition to ROS production. Adenine
nucleotide translocase (ANT), an ADP/ATP carrier located
in the inner mitochondrial membrane, is required for the
synthesis of ATP in the mitochondria. RIP1-dependent
inhibition of ANT is reportedly involved in the pro-
grammed necrosis induced by TNF-α and zVAD-fmk,
whereas the later potentially blocks the ability of ANT to
transport cytoplasmic ADP and thereby induces massive
ATP depletion in mitochondria. The activity of ANT is
potentially affected by interactions with VDAC and cyclo-
philin D (CYPD). Two other potential executional proteins
are cPLA2 and lipoxygenase (LOXs). cPLA2 plays an im-
portant role in TNF-α-induced necrotic cell death in L929
cells and MEFs [34]. LOXs acts as a downstream effector of
PLA2 and leads to the disruption of organelle and plasma
membranes [35]. LOXs is reportedly involved in both apop-
tosis and necrosis induced by TNF-α, although the exact
mechanism has yet to be defined [36, 37].
Necroptosis is able to trigger inflammation. This effect
has been observed in a study using mice with deletion of
FADD [38] or Casp8 [39] in intestinal epithelial cells
(IECs) in which RIP3-dependent cell death caused intes-
tinal inflammation. RIP3-mediated necroptosis may play
a role in the pathogenesis of Crohn’s disease, as evi-
denced by the high RIP3 expression in Paneth cells of
these patients [39]. Necroptosis has been found to
stimulate the immune system to elicit inflammatory
responses and has also been characterized in animal
models of acute pancreatitis, ischemic injury, and neuro-
degeneration [9, 40–42]. RIP3−/− mice are protected
from systemic inflammation caused by TNF stimulation
and experimental sepsis induced by cecal ligation and
puncture (CLP) [43, 44]. RIP1 and RIP3 also play crucialroles in the pathogenesis of Salmonella enterica serovar
and S. typhimurium infection [45]. Necrotic macro-
phages have been observed in atherosclerosis lesions
from both human patients and animals [46]. RIP3-
dependent necroptosis is a key driver for inflammation
in atherosclerosis; RIP3 deficiency alleviates macro-
phage necrosis in advanced atherosclerosis lesions in
atherosclerosis-prone LDL-R−/− or ApoE−/− mice [47].
The contribution of RIP1-dependent necroptosis to
multiple organ failure has also been observed in models
of ischemia reperfusion (IR) and can be rescued by
Nec-1 inhibitor [48–50]. In addition, necroptosis has
been shown to contribute to neuronal damage in neo-
natal brain injury [51].
Taken together, necrosis and necroptosis are en-
dogenous triggers of inflammation that influence host
disease outcomes. Determining the relative contribu-
tion of necroptosis-dependent and -independent path-
ways in inflammation may lead to new and more
specific therapeutic targets.
Apoptosis and inflammation
Apoptosis is one of the major types of cell death and has
been well defined for many years. Two independent
apoptotic signaling cascades, the extrinsic and intrinsic
pathways, have been distinguished [52]. The extrinsic
pathway is triggered by binding of Fas plasma membrane
death receptor to Fas ligand (Fas-L) and other similar
receptors, such as TNFR 1 and its relatives [53]. Fas-L
combines with Fas to form a death complex. The Fas/
Fas-L composite recruits death domain-containing pro-
tein (FADD) and pro-caspase-8, aggregating to become
the death-inducing signaling complex (DISC). Conse-
quently, the protein complex activates pro-caspase-8,
which proceeds to trigger pro-caspase-3, the penultimate
enzyme for the execution of the apoptotic process [54].
The intrinsic pathway also leads to apoptosis but under
the control of mitochondrial pro-enzymes. When a cell
is stimulated by either extracellular stimuli or intracellu-
lar signals, the outer mitochondrial membranes become
permeable to internal cytochrome c, which is then
released into the cytosol. Cytochrome c associates with
the adaptor protein Apaf-1 to form the apoptosome,
which triggers downstream caspase 9 [55]. Once acti-
vated, caspases-8, −9, and −10 process the executioner
caspases-3 and −7. Mature caspases-3 and −7 cleave a
large set of substrates, ultimately resulting in the charac-
teristic morphological and biochemical hallmarks of
apoptosis, such as phosphatidylserine exposure, nuclear
condensation, membrane blebbing, and genomic DNA
fragmentation.
Many factors and signaling pathways that are activated
by inflammation are involved in the regulation of cell
apoptosis. Absent in melanoma 2 (AIM2), a member of
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plasm, has been found to activate caspase-3 in parallel
with caspase-1 [56]. AIM2 can recognize DNA released
by the cytosolic bacteria [57], whereas NLRP3, another
member of the cytoplasmic PRRs, responds to the bac-
terial pore-forming toxin nigericin [58], both of which
elicit apoptotic caspase activation [59, 60]. Apoptotic
responses can be observed in wild type cells responding
to AIM2 or NLRP3 stimuli [58]. AIM2 and NLRP3
inflammasome-dependent apoptosis requires caspase-8,
which is recruited to the inflammasome through inter-
action between its DED domains and the PYD of
apoptosis-associated speck-like protein containing a
caspase activation and recruitment domains (CARD),
an adaptor molecule of the inflammasome [57, 58, 61].
In contrast, BCL-2 can negatively regulate NLRP3
inflammasome activation by preventing the cytosolic
release of mitochondrial DNA [62].
Apoptotic cells can expose “eat me” signals, which
are either newly expressed molecules or existing mole-
cules modified by oxidation, to initiate phagocytosis of
the apoptotic cells [63]. The process of phagocytosis of
apoptotic cells represents an anti-inflammatory mech-
anism. Phosphatidyl serine (PS) localized to the outer
leaflet of the plasma membrane is the predominant “eat
me” molecule upon apoptosis [63, 64]. Specific mole-
cules such as milk fat globule epidermal growth factor
8 (MFG-E8) links PS to phagocyte avb3 integrin [63],
whereas growth-arrest-specific 6 (GAS6) links PS to the
receptor tyrosine kinase MER [63]. PS acts as a ligand
for the T-cell immunoglobulin domain and mucin do-
main (TIM)-4 molecule on macrophages and dendritic
cells (DC) [65], and TIM-4 helps promote the uptake of
apoptotic cells [66]. Two other molecules, brain-
specific angiogenesis inhibitor 1 (BAI1) and stabilin-2,
have also been shown to mediate uptake of apoptotic
cells via recognition of PS [67, 68].
Apoptotic cells are rarely detected under physiological
conditions, but the presence of uncleared apoptotic cells
has been linked to several different diseases, including
infection and inflammation. PAMPs and DAMPs are
detected by the tissue-resident cells in response to an
acute infection or tissue injury. Next, leukocytes aggre-
gate near to the site of inflammation; innate immune
cells, such as neutrophils, are often the first cells to
appear, whereas mononuclear cells and macrophages ac-
cumulate later [69]. This initial robust immune response
is designed to destroy invading pathogens and enhance
tissue repair [70, 71]. After eliminating the initial threat,
leukocyte recruitment ceases, and the previously re-
cruited cells are disposed. The main clearance route of
leukocytes is local neutrophil apoptosis and subsequent
phagocytosis [72, 73], although they can be cleared
through transepithelial migration into the airway lumenin the context of lung inflammation [74] or via lymphatic
vessels [75]. The phagocytosis of pathogens, such as
Escherichia coli or Staphylococcus aureus, promotes neu-
trophil apoptosis following neutrophil recruitment, which
is termed phagocytosis-induced cell death (PICD) [76].
This response is believed to be primarily protective for the
host, and incidentally, pharmacological acceleration of
neutrophil apoptosis is protective in pneumococcal
meningitis by reducing the incidence of brain hemorrhage
[77]. The failed clearance of apoptotic neutrophils can
lead to a prolonged inflammatory response, and this
phenomenon has been observed in disease, including
chronic obstructive pulmonary disease (COPD) [78],
pulmonary fibrosis [79] and cystic fibrosis [80]. The
production of ROS by neutrophils involves this
impaired phagocytosis process, in which ROS activate
the GTPase RHOA in surrounding phagocytes and re-
duces apoptotic cell engulfment by neighboring cells
[81–84]. Alveolar macrophages from patients with
severe asthma and children with poorly controlled
asthma are defective in clearing apoptotic cells [85, 86].
As the mainstay of treatment in asthma, corticosteroids
not only induce eosinophil apoptosis [87] but also en-
hance monocyte-derived macrophage engulfment [88].
The mechanism underlying the enhanced clearance
seems dependent on the binding of protein S to apop-
totic cells and the upregulation of tyrosine-protein
kinase MER on the surface of macrophages [89].
Recently, airway epithelial cells have been found to be
capable of engulfing neighboring apoptotic cells, and
deficiency of this engulfing function increases pro-
inflammatory mediator production and exacerbates
airway inflammation [90]. Apoptotic cells are well
established to induce the synthesis of anti-inflammatory
mediators such as TGF-β, prostaglandin E2, and platelet
activating factor by macrophages [91, 92].
To summarize, contrary to traditional model, specific
PRRs may activate apoptotic signaling pathways. More
importantly, the clearance of apoptotic cells and neutro-
phil apoptosis in the host further affects inflammation.
Therapeutic induction of neutrophil apoptosis at the
inflammatory site may be a powerful pro-resolution
intervention and could fulfill the clinical need to prevent
the harmful consequences of inflammation.
Pyroptosis and inflammation
Pyroptosis is a form of cell death that depends on
caspase-1 activation. Pyroptosis features rapid plasma-
membrane rupture and release of proinflammatory
intracellular content. Cell lysis during pyroptosis results
from caspase-1-mediated processes [93–101]. Plasma
membrane pores dependent on caspase-1 dissipate
cellular ionic gradients, producing a net increased
osmotic pressure, water influx, cell swelling, and
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tory intracellular content [102]. Cell death due to pyr-
optosis results in a measurable cellular size increase and
cleavage of chromosomal DNA [95, 97, 102–105].
The inflammasome, a caspase-1-containing complex
that activates the proinflammatory cytokines IL-1β and
IL-18 and results in proinflammatory cell death, is one
of the drivers of pyroptosis. The inflammasome activates
caspase-1 through a Nod-like receptor (NLRP1, 3, 6, 7,
12, NLRC4), AIM2, or Pyrin, all of which contain a
CARD or pyrin domain (PYD) [106, 107]. Many inflam-
masomes recruit the ASC adaptor via homotypic inter-
actions. Additional ASC molecules are incorporated via
CARD-CARD and PYD-PYD interactions, until all ASC
molecules are collected into a single focus. The recruit-
ment of procaspase-1 into the ASC focus via CARD-
CARD interactions results in its dimerization and
proximity-induced autoproteolytic processing into the
p10 and p20 subunits. This processed and catalytically
active caspase-1 cleaves pro-IL-1β and pro-IL-18.
We recently reported that HMGB1 acting through
RAGE on macrophages (or macrophage membrane)
triggers dynamin-dependent endocytosis of HMGB1,
which in turn initiates a cascade of cellular and molecu-
lar events. These events include cathepsin B activation
and release from ruptured lysosomes, followed by pyrop-
tosome formation and caspase-1 activation, which servesFig. 2 Model of macrophage endocytosis of HMGB1 induces pyroptosis. HMG
endocytosis of HMGB1, which in turn initiates a cascade of cellular and molec
lysosomes followed by pyroptosome formation and caspase-1 activation, whias a mechanism underlying the HMGB1-induced macro-
phage pyroptosis (Fig. 2) [108].
A recent study demonstrated that after pyroptosis,
ASC specks accumulate in the extracellular space, where
they promote further maturation of IL-1β [109]. In
addition, phagocytosis of ASC specks by macrophages
induces lysosomal damage and nucleation of soluble
ASC as well as activation of IL-1β in recipient cells
[109]. These findings indicate that pyroptotic cell-
released inflammasomes serve as danger signals pro-
moting enhanced activation of macrophages.
Pyroptotic cells secrete the inflammatory cytokines IL-
1β and IL-18 following caspase-1 activation. IL-1β is a
potent endogenous pyrogen that stimulates fever,
leukocyte tissue migration and expression of diverse
cytokines and chemokines [110]. IL-18 induces IFNγ
production and is important for the activation of T cells,
macrophages and other cell types [111]. Cytokine secre-
tion occurs through caspase-1-dependent pores in the
plasma membrane. Pharmacological inhibition of cell
lysis does not prevent caspase-1-dependent pore forma-
tion and cytokine secretion, suggesting that lysis is not
required for the release of active IL-1β and IL-18 [102].
Thus, cytokine secretion and cell lysis are both down-
stream consequences of caspase-1-dependent pore for-
mation. Notably, caspase-1 activation cannot trigger
pyroptosis in all cell types; specifically, epithelial cellsB1 acting through RAGE on macrophages triggers dynamin-dependent
ular events. These include CatB activation and release from ruptured
ch promotes HMGB1-induced pyroptosis
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example, caspase-1 activation stimulates lipid production
and membrane repair in response to the pore-forming
toxins aerolysin and α-toxin [112].
In addition to caspase-1, caspase-11 has also been
found to be involved in pyroptosis [113–115]. A recent
study revealed that caspase-11 participates in the process
of non-canonical inflammasome activation downstream
of a cytosolic ligand released from bacteria [116, 117].
Pyroptosis may protect against infection and induces
pathological inflammation. However, exuberant or in-
appropriate caspase-1 activation and pyroptosis can be
detrimental. During infection, caspase-1 activation
helps to clear pathogens, such as Salmonella [118,
119], Francisella [120], Legionella [101, 121], Shigella
[122], Anaplasma phagocytophilum [123], Burkholderia
thailandensis [124], Burkholderia pseudomallei [125] and
Listeria [126]. Mutations in NLR proteins can lead to
improper caspase-1 activation and can cause heredi-
tary autoinflammatory syndromes [127]. Moreover,
caspase-1 is involved in the pathogenesis of several
diseases characterized by inflammation and cell death,
including myocardial infarction [128], cerebral ischaemia
[129], neurodegenerative diseases [130], inflammatory
bowel disease [131], and endotoxic shock [132].
As one of the most recently recognized types of cell
death, pyroptosis exhibits a particular relationship
with common pathogens, and clinic inflammatory
disease for caspase-1 connects to both cell death and
pro-inflammation directly. Pyroptosis and other cas-
pase 1-dependent processes are therefore relevant to
our understanding of the pathophysiology of inflam-
matory disease.
Pyronecrosis and inflammation
Pyronecrosis is another necrosis-like cell death process
that is independent of caspase-1 and caspase-11 but is
dependent on ASC and lysosomal protein cathepsin B.
Pyroptosis results in the cellular secretion of the pro-
inflammatory mediator HMGB1 [133]. Recent studies
have demonstrated that pyronecrosis can be induced by
several pathogens, including Neisseria gonorrhoeae [134],
Toxoplasma gondii parasitophorous [135], Bacillus
anthracis lethal toxin [136] and Staphylococcus aureus
[137]. The mechanism underlying pyronecrosis remains
unclear at present and requires further investigation.
NETosis and inflammation
NETosis is a special form of polymorphonuclear
neutrophil (PMN) death that releases neutrophil extra-
cellular traps (NETs) [138]. NETs are web-like struc-
tures released by neutrophils that are composed of
decondensed chromatin in complex with different neu-
trophil proteins that can capture, neutralize, and killmicrobes. These large extracellular structures provide a
physical barrier to prevent microbial dissemination and
increase the local concentration of antimicrobial effectors
[139, 140]. There are two types of NETosis that can be
distinguished by the occurrence time as early and late.
The more frequently observed type is late NETosis, as
NET release via cell death is a slow process (120–
240 min) and is defined as suicidal NETosis. This form
of suicide is an NADPH oxidase–dependent cellular
death process requiring chromatin decondensation,
followed by nuclear envelope disintegration and
mixing of nucleic acids and granule proteins within a
large intracellular vacuole [141]. However, it remains
unclear how oxidants participate in the dismantling of
the nuclear envelope and mixing of the NET compo-
nents. Classically, suicidal NETosis occurs following
stimulation by phorbol myristate acetate (PMA)
through activation of protein kinase C and the Raf–
mitogen-activated protein kinase (MEK)–extracellular
signal-regulated kinase (ERK) pathway. NADPH assists in
the translocation of neutrophil elastase from cytosolic
granules into the nucleus, where it aids in chromatin
breakdown via histone cleavage. Myeloperoxidase (MPO)
is required for chromatin and nuclear envelope break-
down and granular mixing within the NET vacuole. One
hundred twenty minutes after intracellular NET forma-
tion, the neutrophil outer membrane ruptures, and the
mature NET is extruded.
The early form of NETosis occurs rapidly in response
to a pathogen, e.g., after in vitro Staphylococcus aureus
stimulation for 5–60 min. Early NETosis has also been
termed vital NETosis in some studies [142]. In general,
NETosis begins when the nucleus loses its characteris-
tic lobulated architecture. Subsequently, nuclear mem-
branes disassemble, and the chromatin decondenses
into the cytoplasm while the plasma membrane
remains intact. Finally, the plasma membrane bursts,
leading to NET released [138]. This process is mainly
dependent on ROS, such as superoxide generated by
the NADPH oxidase Nox2. This mechanism spares the
PMN outer membrane, thereby allowing the PMN to
continue to function, even to the point of becoming
anuclear. There are three major differences between
suicidal NETosis and vital NETosis, including the
nature of the inciting stimuli and the timing, the func-
tional capacity of the PMNs during NET release, and
the mechanisms employed to make and release NETs.
In addition to PMN, NETosis has also been observed in
eosinophils and mast cells [143]. Therefore, the more
generalized term ‘ETosis’ maybe more accurate [144].
NETs can kill a number of pathogenic bacteria directly,
beyond just capturing and immobilization [145–148].
Studies demonstrate that NETs can inactivate bacterial
virulence factors, such as IpaB from S. flexneri [138].
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fumigatus via long pentraxin 3 [149]. NETs generated
from PMNs can inhibit the growth of Aspergillus [145]
and kill C. albicanscan, even the opportunistic pathogen
P. aeruginosa [150]. The gram-negative bacterium K.
pneumoniae is not sufficient to induce NETosis in isolated
neutrophils ex vivo but is a good inducer in a mouse lung
infection model [151]. Human immunodeficiency virus
(HIV)-1 has been shown to induce NETosis through a cell
death pathway [152]. Feline leukemia virus (FeLV) was
able to inhibit neutrophil activation by inhibiting the acti-
vation of PKC to reduce ROS production [153].
Numerous types of inflammation are associated with
NETs and NETosis. NETs are observed in acute lung
injury (ALI) models of both infection- or sterile- related
by influenza virus [154, 155], bacteria or bacterial com-
ponent LPS [156–158], fungi [148, 159, 160], and trans-
fusion [161, 162]. Among them, human neutrophil
antigen (HNA)-3a causes the most severe transfusion-
related ALI and has been shown to promote NETosis in
human neutrophils in vitro [161]. Extracellular neutro-
phil elastase release via NETosis may be an important
cause of lung tissue damage and cystic fibrosis progres-
sion [163]. NETs have been shown to form scaffolds in
circulation that promote thrombus formation by inter-
acting with the endothelium, platelets, coagulation
factors and red blood cells, which cause deep vein
thrombosis. IL-8 and ROS release from endothelial cells
can recruit and trigger neutrophils to form NETs, which
subsequently promote damage to the endothelium
through the binding of histones [164].
As a specific cell death type for neutrophils, NETosis
help capture numerous pathogenic bacteria and virus.
Further insight into the interaction between NETs and
invaders would deepen the understanding of the
inflammation process. Furthermore, NETotic products
could be treated as prognostic biomarkers for inflam-
matory disorders, and whether the produces correlate
with clinical outcome in a variety of diseases requires
further translational investigation.
Autophagy and inflammation
Autophagy is a genetically regulated and evolutionarily
conserved pathway for the degradation of subcellular
components [165, 166]. Autophagy has previously been
classified as a form of programmed cell death to describe
a form of caspase-independent necrosis-like cell death
associated with the accumulation of autophagosomes in
cells [167]. This classification is now controversial, and
the casual relationship between autophagy and cell death
remains uncertain [168, 169].
Autophagy formation begins when an autophagic iso-
lation membrane (also known as a phagophore) engulfs
a portion of cytoplasm [170]. Beclin 1, the serine/threonine protein kinase ULK1, autophagy-related LC3
proteins, and γ-aminobutyric acid receptor-associated
proteins are key regulators of phagophore formation [170].
A phagophore sequesters captured cytoplasmic cargo, and
a double-membraned autophagosome is formed following
elongation and closure. Autophagosome formation is
largely controlled by mammalian target of rapamycin
(mTOR). Inhibition of mTOR leads to the interaction
between ULK1 and AMPK [171, 172], which in turn
recruits the type III PI3 kinase VPS34 to promote the
development of autophagosome [173, 174]. The deg-
radation of the captured cargo begins when the
double-membraned autophagosome matures into a
single membrane-delimited autolysosome [175, 176].
Following this step, lysosomes can be recycled from
autolysosomes, thereby permitting the cell to reuse a
critical component required for further autophagy.
PRR signaling induced by PAMPs and DAMPs can
activate autophagy. For instance, TLRs can cooperate
with autophagy in response to PAMPs [177, 178], and
NLRs interact with ATGs to localize autophagy [179,
180]. Inflammatory cytokines such as IL-1 family mem-
bers [181, 182] and IFNγ [183–185] are also involved in
the activation of autophagy, whereas TH2 cell-associated
cytokines, IL-4 and IL-13, inhibit autophagy [184].
Multiple studies have confirmed the important role of
autophagy during the infection process. Autophagy pro-
tects organism from infectious disease by degrading
intracellular bacteria, viruses, and protozoan pathogens
[186–188].
The role of autophagy in regulating inflammation has
been demonstrated in Crohn’s disease and sepsis.
Crohn’s disease is a type of chronic inflammation. Poly-
morphisms in the genes encoding the autophagy-related
proteins Atg2a, Atg4a, Atg4d, death-associated protein,
immunity-related GTPase family M protein (IRGM), and
ULK-1 have been found to be associated with suscepti-
bility to Crohn’s disease [189–191]. NOD2 mutations
cause impairment in autophagosome induction and bac-
terial clearance [179]. Autophagy formation downstream
of NOD2 activation controls IL-1β and IL-6 release
[192, 193] and results in the tolerogenic presentation of
commensal bacterial components on MHC class II com-
plexes in dendrite cells [180]. Inhibition of autophagy in
septic mice boosts inflammatory cytokine levels and
increases mortality. This effect may due to the failure to
clear damaged or dysfunctional mitochondria, which
activate the NLRP3 inflammasome [194]. We have re-
cently demonstrated that hemorrhagic shock (HS) acting
through HMGB1/TLR4 signaling upregulates NOD2
expression in alveolar macrophages (AM) and subse-
quently sensitizes AM to the NOD2 ligand MDP, which
leads to exacerbated inflammation in the lung. Moreover,
upregulated NOD2 signaling induces autophagy in AM,
Yang et al. Military Medical Research  (2015) 2:12 Page 8 of 12which in turn negatively regulates lung inflammation via a
mechanism that involves suppression of NOD2-RIP2
signaling and inflammasome activation. PMNs coun-
teract this anti-inflammatory effect of autophagy via a
NAD(P)H oxidase-derived ROS mechanism; therefore,
PMNs enhance post-HS lung inflammation [195].
Although the relationship between autophagy and
cell death remains uncertain, several members of the
inflammation process are involved in autophagy. The
function of autophagy in related inflammatory diseases
requires further investigation. A better understanding
of the relevance of the contribution of autophagy to
inflammatory diseases has great clinical potential.Conclusion and prospective
Emerging evidence has demonstrated the tight links
between cell death and inflammation. A better appre-
ciation of the cross-regulatory relationships between
different forms of cell death and pathways will be cru-
cial for understanding their roles in the inflammation
process. It is important that we realize the therapeutic
possibility of targeting programed cell death in pa-
tients. Our understanding of the molecular pathways
of programed cell death will allow the development of
reagents that control cell death, thereby serving as a novel
strategy for interventions in inflammatory diseases. Some
types of cell death that do not seem to be related to
inflammation may also be considered in future studies in
light of their possible interaction with inflammation; these
approaches will help us better understand the entire
inflammatory process network.Abbreviations
AIM: Absent in melanoma; ALI: Acute lung injury; AM: Alveolar macrophages;
ANT: Adenine nucleotide translocase; BAI: Brain-specific angiogenesis
inhibitor; CARD: Caspase activation and recruitment domains; CLP: Cecal
ligation and puncture; COPD: Chronic obstructive pulmonary disease;
CYPD: Cyclophilin D; DAMPs: Damage-associated molecular patterns;
DC: Dendritic cells; DISC: Death-inducing signaling complex; ERK: Extracellular
signal-regulated kinase; FADD: Fas-associated death domain; Fas-L: Fas
ligand; FeLV: Feline leukemia virus; GAS: Growth-arrest-specific; HIV: Human
immunodeficiency virus; HMGB1: High-mobility group box 1; HNA: Human
neutrophil antigen; HS: Hemorrhagic shock; IAPs: Inhibitor of apoptosis
proteins; IECs: Intestinal epithelial cells; IR: Ischemia reperfusion;
IRGM: Immunity-related GTPase family M protein; LOXs: Lipoxygenase;
MEK: Raf-mitogen-activated protein kinase; MFG-E: Milk fat globule epidermal
growth factor; MPO: Myeloperoxidase; mTOR: Mammalian target of
rapamycin; NETs: Neutrophil extracellular traps; PICD: Phagocytosis-induced
cell death; PIPs: Phosphatidylinositol phosphates; PMA: Phorbol myristate
acetate; PMN: Polymorphonuclear neutrophil; PRRs: Pattern recognition
receptors; PS: Phosphatidyl serine; PYD: Pyrin domain; RAGE: Receptor for
advanced-glycation end-products; RIP: Receptor-interacting protein kinase;
ROS: Reactive oxygen species; Nec-1: Necrostatin-1; SODD: Silencer of death
domains; TIM: T-cell immunoglobulin domain and mucin domain;
TNFR: Tumor necrosis factor receptor; TRADD: TNF-α receptor-associated
death domain; TRAF: TNF-α receptor associated factor.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
YY collected the data and drafted the manuscript. GJ conceived and
designed the study. PZ revised the manuscript. JF conceived and designed
the study, reviewed and finalized the manuscript. All authors read and
approved the final manuscript.Acknowledgment
This work was supported by the USA National Institutes of Health Grant R01-
HL-079669, USA National Institutes of Health Center Grant P50-GM-53789,
and a USA VA Merit Award.
Author details
1Department of Surgery, University of Pittsburgh School of Medicine,
Pittsburgh, PA 15213, USA. 2Department of Thoracic Surgery, Shanghai
Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433,
China. 3Research and Development, Veterans Affairs Pittsburgh Healthcare
System, Pittsburgh, PA 15240, USA.
Received: 2 February 2015 Accepted: 11 May 2015References
1. Suzanne M, Steller H. Shaping organisms with apoptosis. Cell Death Differ.
2013;20(5):669–75.
2. Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the
cellular level. Nat Rev Mol Cell Biol. 2008;9(3):231–41.
3. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in
inflammation and cancer. Annu Rev Immunol. 2010;28:367–88.
4. Sun L, Wang H, Wang Z, He S, Chen S, Liao D, et al. Mixed lineage kinase
domain-like protein mediates necrosis signaling downstream of RIP3 kinase.
Cell. 2012;148(1–2):213–27.
5. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular
mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell
Biol. 2010;11(10):700–14.
6. Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, et al.
Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates
programmed necrosis and virus-induced inflammation. Cell.
2009;137(6):1112–23.
7. Feng S, Yang Y, Mei Y, Ma L, Zhu DE, Hoti N, et al. Cleavage of RIP3
inactivates its caspase-independent apoptosis pathway by removal of kinase
domain. Cell Signal. 2007;19(10):2056–67.
8. Teng X, Degterev A, Jagtap P, Xing X, Choi S, Denu R, et al. Structure-
activity relationship study of novel necroptosis inhibitors. Bioorg Med Chem
Lett. 2005;15(22):5039–44.
9. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, et al. Chemical
inhibitor of nonapoptotic cell death with therapeutic potential for ischemic
brain injury. Nat Chem Biol. 2005;1(2):112–9.
10. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV,
et al. Molecular definitions of cell death subroutines: recommendations of
the Nomenclature Committee on Cell Death 2012. Cell Death Differ.
2012;19(1):107–20.
11. Andera L. Signaling activated by the death receptors of the TNFR family.
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub.
2009;153(3):173–80.
12. Wertz IE, Dixit VM. Ubiquitin-mediated regulation of TNFR1 signaling.
Cytokine Growth Factor Rev. 2008;19(3–4):313–24.
13. Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E, et al.
Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation.
Proc Natl Acad Sci U S A. 2008;105(33):11778–83.
14. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K,
et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha
(TNFalpha)-induced NF-kappaB activation. J Biol Chem. 2008;283(36):24295–9.
15. O'Donnell MA, Legarda-Addison D, Skountzos P, Yeh WC, Ting AT.
Ubiquitination of RIP1 regulates an NF-kappaB-independent cell-death
switch in TNF signaling. Current Biology: CB. 2007;17(5):418–24.
16. Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M, et al.
cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing
intracellular cell death complex differentially regulated by cFLIP isoforms.
Mol Cell. 2011;43(3):449–63.
Yang et al. Military Medical Research  (2015) 2:12 Page 9 of 1217. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, et al.
cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases
that promote RIP1 ubiquitination. Mol Cell. 2008;30(6):689–700.
18. Declercq W, Vanden Berghe T, Vandenabeele P. RIP kinases at the
crossroads of cell death and survival. Cell. 2009;138(2):229–32.
19. Zhao J, Jitkaew S, Cai Z, Choksi S, Li Q, Luo J, et al. Mixed lineage kinase
domain-like is a key receptor interacting protein 3 downstream component
of TNF-induced necrosis. Proc Natl Acad Sci U S A. 2012;109(14):5322–7.
20. Orozco S, Yatim N, Werner MR, Tran H, Gunja SY, Tait SW, et al. RIPK1 both
positively and negatively regulates RIPK3 oligomerization and necroptosis.
Cell Death Differ. 2014;21(10):1511–21.
21. Wu XN, Yang ZH, Wang XK, Zhang Y, Wan H, Song Y, et al. Distinct roles of
RIP1-RIP3 hetero- and RIP3-RIP3 homo-interaction in mediating necroptosis.
Cell Death Differ. 2014;21(11):1709–20.
22. Murphy JM, Czabotar PE, Hildebrand JM, Lucet IS, Zhang JG, Alvarez-Diaz S,
et al. The pseudokinase MLKL mediates necroptosis via a molecular switch
mechanism. Immunity. 2013;39(3):443–53.
23. Kaiser WJ, Sridharan H, Huang C, Mandal P, Upton JW, Gough PJ, et al. Toll-
like receptor 3-mediated necrosis via TRIF, RIP3, and MLKL. J Biol Chem.
2013;288(43):31268–79.
24. Polykratis A, Hermance N, Zelic M, Roderick J, Kim C, Van TM, et al. Cutting
edge: RIPK1 Kinase inactive mice are viable and protected from TNF-induced
necroptosis in vivo. J Immunol. 2014;193(4):1539–43.
25. Thapa RJ, Nogusa S, Chen P, Maki JL, Lerro A, Andrake M, et al. Interferon-
induced RIP1/RIP3-mediated necrosis requires PKR and is licensed by FADD
and caspases. Proc Natl Acad Sci U S A. 2013;110(33):E3109–18.
26. Upton JW, Kaiser WJ, Mocarski ES. DAI/ZBP1/DLM-1 complexes with RIP3 to
mediate virus-induced programmed necrosis that is targeted by murine
cytomegalovirus vIRA. Cell Host Microbe. 2012;11(3):290–7.
27. Chen X, Li W, Ren J, Huang D, He WT, Song Y, et al. Translocation of mixed
lineage kinase domain-like protein to plasma membrane leads to necrotic
cell death. Cell Res. 2014;24(1):105–21.
28. Vanden Berghe T, Vanlangenakker N, Parthoens E, Deckers W, Devos M,
Festjens N, et al. Necroptosis, necrosis and secondary necrosis converge on
similar cellular disintegration features. Cell Death Differ. 2010;17(6):922–30.
29. Sakon S, Xue X, Takekawa M, Sasazuki T, Okazaki T, Kojima Y, et al. NF-kappaB
inhibits TNF-induced accumulation of ROS that mediate prolonged MAPK
activation and necrotic cell death. EMBO J. 2003;22(15):3898–909.
30. Jezek P, Hlavata L. Mitochondria in homeostasis of reactive oxygen species
in cell, tissues, and organism. Int J Biochem Cell Biol. 2005;37(12):2478–503.
31. Chen Q, Vazquez EJ, Moghaddas S, Hoppel CL, Lesnefsky EJ. Production of
reactive oxygen species by mitochondria: central role of complex III. J Biol
Chem. 2003;278(38):36027–31.
32. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev
Immunol. 2004;4(3):181–9.
33. Wu YT, Tan HL, Huang Q, Sun XJ, Zhu X, Shen HM. zVAD-induced
necroptosis in L929 cells depends on autocrine production of TNFalpha
mediated by the PKC-MAPKs-AP-1 pathway. Cell Death Differ.
2011;18(1):26–37.
34. Hayakawa M, Ishida N, Takeuchi K, Shibamoto S, Hori T, Oku N, et al.
Arachidonic acid-selective cytosolic phospholipase A2 is crucial in the cyto-
toxic action of tumor necrosis factor. J Biol Chem. 1993;268(15):11290–5.
35. van Leyen K, Duvoisin RM, Engelhardt H, Wiedmann M. A function for
lipoxygenase in programmed organelle degradation. Nature.
1998;395(6700):392–5.
36. Maccarrone M, Melino G, Finazzi-Agro A. Lipoxygenases and their involvement
in programmed cell death. Cell Death Differ. 2001;8(8):776–84.
37. Festjens N, Kalai M, Smet J, Meeus A, Van Coster R, Saelens X, et al.
Butylated hydroxyanisole is more than a reactive oxygen species scavenger.
Cell Death Differ. 2006;13(1):166–9.
38. Welz PS, Wullaert A, Vlantis K, Kondylis V, Fernandez-Majada V, Ermolaeva M,
et al. FADD prevents RIP3-mediated epithelial cell necrosis and chronic
intestinal inflammation. Nature. 2011;477(7364):330–4.
39. Gunther C, Martini E, Wittkopf N, Amann K, Weigmann B, Neumann H, et al.
Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and terminal
ileitis. Nature. 2011;477(7364):335–9.
40. He S, Wang L, Miao L, Wang T, Du F, Zhao L, et al. Receptor interacting
protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell.
2009;137(6):1100–11.
41. Upton JW, Kaiser WJ, Mocarski ES. Virus inhibition of RIP3-dependent
necrosis. Cell Host Microbe. 2010;7(4):302–13.42. Artal-Sanz M, Tavernarakis N. Proteolytic mechanisms in necrotic cell death
and neurodegeneration. FEBS Lett. 2005;579(15):3287–96.
43. Duprez L, Takahashi N, Van Hauwermeiren F, Vandendriessche B, Goossens
V, Vanden Berghe T, et al. RIP kinase-dependent necrosis drives lethal
systemic inflammatory response syndrome. Immunity. 2011;35(6):908–18.
44. Linkermann A, Brasen JH, De Zen F, Weinlich R, Schwendener RA, Green DR,
et al. Dichotomy between RIP1- and RIP3-mediated necroptosis in tumor
necrosis factor-alpha-induced shock. Mol Med. 2012;18:577–86.
45. Robinson N, McComb S, Mulligan R, Dudani R, Krishnan L, Sad S. Type I
interferon induces necroptosis in macrophages during infection with
Salmonella enterica serovar Typhimurium. Nat Immunol. 2012;13(10):954–62.
46. Tabas I. Macrophage death and defective inflammation resolution in
atherosclerosis. Nat Rev Immunol. 2010;10(1):36–46.
47. Lin J, Li H, Yang M, Ren J, Huang Z, Han F, et al. A role of RIP3-mediated
macrophage necrosis in atherosclerosis development. Cell Rep.
2013;3(1):200–10.
48. Linkermann A, Brasen JH, Himmerkus N, Liu S, Huber TB, Kunzendorf U,
et al. Rip1 (receptor-interacting protein kinase 1) mediates necroptosis and
contributes to renal ischemia/reperfusion injury. Kidney Int.
2012;81(8):751–61.
49. Oerlemans MI, Liu J, Arslan F, den Ouden K, van Middelaar BJ, Doevendans
PA, et al. Inhibition of RIP1-dependent necrosis prevents adverse cardiac
remodeling after myocardial ischemia-reperfusion in vivo. Basic Res Cardiol.
2012;107(4):270.
50. Rosenbaum DM, Degterev A, David J, Rosenbaum PS, Roth S, Grotta JC, et al.
Necroptosis, a novel form of caspase-independent cell death, contributes to
neuronal damage in a retinal ischemia-reperfusion injury model. J Neurosci
Res. 2010;88(7):1569–76.
51. Chavez-Valdez R, Martin LJ, Northington FJ. Programmed Necrosis: A Prominent
Mechanism of Cell Death following Neonatal Brain Injury. Neurol Res Int.
2012;2012:257563.
52. Eum KH, Lee M. Crosstalk between autophagy and apoptosis in the regulation
of paclitaxel-induced cell death in v-Ha-ras-transformed fibroblasts. Mol Cell
Biochem. 2011;348(1–2):61–8.
53. Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, et al. Programmed cell
death pathways in cancer: a review of apoptosis, autophagy and
programmed necrosis. Cell Prolif. 2012;45(6):487–98.
54. Fadeel B, Orrenius S. Apoptosis: a basic biological phenomenon with wide-
ranging implications in human disease. J Intern Med. 2005;258(6):479–517.
55. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer
therapy. CA Cancer J Clin. 2005;55(3):178–94.
56. Roberts TL, Idris A, Dunn JA, Kelly GM, Burnton CM, Hodgson S, et al. HIN-
200 proteins regulate caspase activation in response to foreign cytoplasmic
DNA. Science. 2009;323(5917):1057–60.
57. Pierini R, Juruj C, Perret M, Jones CL, Mangeot P, Weiss DS, et al. AIM2/
ASC triggers caspase-8-dependent apoptosis in Francisella-infected
caspase-1-deficient macrophages. Cell Death Differ. 2012;19(10):1709–21.
58. Sagulenko V, Thygesen SJ, Sester DP, Idris A, Cridland JA, Vajjhala PR, et al.
AIM2 and NLRP3 inflammasomes activate both apoptotic and pyroptotic
death pathways via ASC. Cell Death Differ. 2013;20(9):1149–60.
59. Abdelaziz DH, Gavrilin MA, Akhter A, Caution K, Kotrange S, Khweek AA, et al.
Asc-dependent and independent mechanisms contribute to restriction of
legionella pneumophila infection in murine macrophages. Front Microbiol.
2011;2:18.
60. Puri AW, Broz P, Shen A, Monack DM, Bogyo M. Caspase-1 activity is
required to bypass macrophage apoptosis upon Salmonella infection.
Nat Chem Biol. 2012;8(9):745–7.
61. Masumoto J, Dowds TA, Schaner P, Chen FF, Ogura Y, Li M, et al. ASC is an
activating adaptor for NF-kappa B and caspase-8-dependent apoptosis.
Biochem Biophys Res Commun. 2003;303(1):69–73.
62. Dondelinger Y, Aguileta MA, Goossens V, Dubuisson C, Grootjans S,
Dejardin E, et al. RIPK3 contributes to TNFR1-mediated RIPK1 kinase-
dependent apoptosis in conditions of cIAP1/2 depletion or TAK1 kinase
inhibition. Cell Death Differ. 2013;20(10):1381–92.
63. Ravichandran KS, Lorenz U. Engulfment of apoptotic cells: signals for a
good meal. Nat Rev Immunol. 2007;7(12):964–74.
64. Martin SJ, Reutelingsperger CP, McGahon AJ, Rader JA, van Schie RC,
LaFace DM, et al. Early redistribution of plasma membrane
phosphatidylserine is a general feature of apoptosis regardless of the
initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp
Med. 1995;182(5):1545–56.
Yang et al. Military Medical Research  (2015) 2:12 Page 10 of 1265. Miyanishi M, Tada K, Koike M, Uchiyama Y, Kitamura T, Nagata S.
Identification of Tim4 as a phosphatidylserine receptor. Nature.
2007;450(7168):435–9.
66. Kobayashi N, Karisola P, Pena-Cruz V, Dorfman DM, Jinushi M, Umetsu SE,
et al. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate
uptake of apoptotic cells. Immunity. 2007;27(6):927–40.
67. Park D, Tosello-Trampont AC, Elliott MR, Lu M, Haney LB, Ma Z, et al. BAI1 is
an engulfment receptor for apoptotic cells upstream of the ELMO/Dock180/
Rac module. Nature. 2007;450(7168):430–4.
68. Park SY, Jung MY, Kim HJ, Lee SJ, Kim SY, Lee BH, et al. Rapid cell corpse
clearance by stabilin-2, a membrane phosphatidylserine receptor. Cell Death
Differ. 2008;15(1):192–201.
69. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, et al.
Resolution of inflammation: state of the art, definitions and terms. FASEB J.
2007;21(2):325–32.
70. Zemans RL, Briones N, Campbell M, McClendon J, Young SK, Suzuki T,
et al. Neutrophil transmigration triggers repair of the lung epithelium
via beta-catenin signaling. Proc Natl Acad Sci U S A.
2011;108(38):15990–5.
71. Farnworth SL, Henderson NC, Mackinnon AC, Atkinson KM, Wilkinson T,
Dhaliwal K, et al. Galectin-3 reduces the severity of pneumococcal pneumonia
by augmenting neutrophil function. Am J Pathol. 2008;172(2):395–405.
72. Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PM, Haslett C.
Macrophage phagocytosis of aging neutrophils in inflammation.
Programmed cell death in the neutrophil leads to its recognition by
macrophages. J Clin Invest. 1989;83(3):865–75.
73. Haslett C. Granulocyte apoptosis and its role in the resolution and control
of lung inflammation. Am J Respir Crit Care Med. 1999;160(5 Pt 2):S5–11.
74. Persson CG, Uller L. Resolution of cell-mediated airways diseases. Respir Res.
2010;11:75.
75. Beauvillain C, Cunin P, Doni A, Scotet M, Jaillon S, Loiry ML, et al. CCR7 is involved
in the migration of neutrophils to lymph nodes. Blood. 2011;117(4):1196–204.
76. Watson RW, Redmond HP, Wang JH, Condron C, Bouchier-Hayes D.
Neutrophils undergo apoptosis following ingestion of Escherichia coli.
J Immunol. 1996;156(10):3986–92.
77. Koedel U, Frankenberg T, Kirschnek S, Obermaier B, Hacker H, Paul R, et al.
Apoptosis is essential for neutrophil functional shutdown and determines
tissue damage in experimental pneumococcal meningitis. PLoS Pathog.
2009;5(5):e1000461.
78. Hodge S, Hodge G, Scicchitano R, Reynolds PN, Holmes M. Alveolar
macrophages from subjects with chronic obstructive pulmonary disease are
deficient in their ability to phagocytose apoptotic airway epithelial cells.
Immunol Cell Biol. 2003;81(4):289–96.
79. Morimoto K, Janssen WJ, Terada M. Defective efferocytosis by alveolar
macrophages in IPF patients. Respir Med. 2012;106(12):1800–3.
80. Vandivier RW, Fadok VA, Ogden CA, Hoffmann PR, Brain JD, Accurso FJ,
et al. Impaired clearance of apoptotic cells from cystic fibrosis airways.
Chest. 2002;121(3 Suppl):89S.
81. McPhillips K, Janssen WJ, Ghosh M, Byrne A, Gardai S, Remigio L, et al.
TNF-alpha inhibits macrophage clearance of apoptotic cells via cytosolic
phospholipase A2 and oxidant-dependent mechanisms. J Immunol.
2007;178(12):8117–26.
82. Nakaya M, Tanaka M, Okabe Y, Hanayama R, Nagata S. Opposite effects of
rho family GTPases on engulfment of apoptotic cells by macrophages. J Biol
Chem. 2006;281(13):8836–42.
83. Moon C, Lee YJ, Park HJ, Chong YH, Kang JL. N-acetylcysteine inhibits RhoA
and promotes apoptotic cell clearance during intense lung inflammation.
Am J Respir Crit Care Med. 2010;181(4):374–87.
84. Cepkova M, Matthay MA. Pharmacotherapy of acute lung injury and the
acute respiratory distress syndrome. J Intensive Care Med.
2006;21(3):119–43.
85. Fitzpatrick AM, Holguin F, Teague WG, Brown LA. Alveolar macrophage
phagocytosis is impaired in children with poorly controlled asthma. J
Allergy Clin Immunol. 2008;121(6):1372–8. 1378 e1371-1373.
86. Huynh ML, Malcolm KC, Kotaru C, Tilstra JA, Westcott JY, Fadok VA, et al.
Defective apoptotic cell phagocytosis attenuates prostaglandin E2 and
15-hydroxyeicosatetraenoic acid in severe asthma alveolar macrophages.
Am J Respir Crit Care Med. 2005;172(8):972–9.
87. Hotchkiss RS, Tinsley KW, Swanson PE, Chang KC, Cobb JP, Buchman TG,
et al. Prevention of lymphocyte cell death in sepsis improves survival in
mice. Proc Natl Acad Sci U S A. 1999;96(25):14541–6.88. Hotchkiss RS, Chang KC, Swanson PE, Tinsley KW, Hui JJ, Klender P, et al.
Caspase inhibitors improve survival in sepsis: a critical role of the
lymphocyte. Nat Immunol. 2000;1(6):496–501.
89. Methot N, Huang J, Coulombe N, Vaillancourt JP, Rasper D, Tam J, et al.
Differential efficacy of caspase inhibitors on apoptosis markers during sepsis
in rats and implication for fractional inhibition requirements for
therapeutics. J Exp Med. 2004;199(2):199–207.
90. Juncadella IJ, Kadl A, Sharma AK, Shim YM, Hochreiter-Hufford A, Borish L, et al.
Apoptotic cell clearance by bronchial epithelial cells critically influences airway
inflammation. Nature. 2013;493(7433):547–51.
91. Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM.
Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory
cytokine production through autocrine/paracrine mechanisms involving TGF-beta,
PGE2, and PAF. J Clin Invest. 1998;101(4):890–8.
92. Huynh ML, Fadok VA, Henson PM. Phosphatidylserine-dependent ingestion of
apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation.
J Clin Invest. 2002;109(1):41–50.
93. Hersh D, Monack DM, Smith MR, Ghori N, Falkow S, Zychlinsky A. The
Salmonella invasin SipB induces macrophage apoptosis by binding to
caspase-1. Proc Natl Acad Sci U S A. 1999;96(5):2396–401.
94. Chen Y, Smith MR, Thirumalai K, Zychlinsky A. A bacterial invasin induces
macrophage apoptosis by binding directly to ICE. Embo J. 1996;15(15):3853–60.
95. Bergsbaken T, Cookson BT. Macrophage activation redirects yersinia-infected
host cell death from apoptosis to caspase-1-dependent pyroptosis. PLoS
Pathog. 2007;3(11):e161.
96. Kelk P, Johansson A, Claesson R, Hanstrom L, Kalfas S. Caspase 1
involvement in human monocyte lysis induced by Actinobacillus
actinomycetemcomitans leukotoxin. Infect Immun. 2003;71(8):4448–55.
97. Sun GW, Lu J, Pervaiz S, Cao WP, Gan YH. Caspase-1 dependent
macrophage death induced by Burkholderia pseudomallei. Cell Microbiol.
2005;7(10):1447–58.
98. Fink SL, Bergsbaken T, Cookson BT. Anthrax lethal toxin and Salmonella
elicit the common cell death pathway of caspase-1-dependent pyroptosis
via distinct mechanisms. Proc Natl Acad Sci U S A. 2008;105(11):4312–7.
99. Thumbikat P, Dileepan T, Kannan MS, Maheswaran SK. Mechanisms
underlying Mannheimia haemolytica leukotoxin-induced oncosis and
apoptosis of bovine
alveolar macrophages. Microb Pathog. 2005;38(4):161–72.
100. Ren T, Zamboni DS, Roy CR, Dietrich WF, Vance RE. Flagellin-deficient
Legionella mutants evade caspase-1- and Naip5-mediated macrophage
immunity. PLoS Pathog. 2006;2(3):e18.
101. Molofsky AB, Byrne BG, Whitfield NN, Madigan CA, Fuse ET, Tateda K, et al.
Cytosolic recognition of flagellin by mouse macrophages restricts Legionella
pneumophila infection. J Exp Med. 2006;203(4):1093–104.
102. Fink SL, Cookson BT. Caspase-1-dependent pore formation during
pyroptosis leads to osmotic lysis of infected host macrophages. Cell
Microbiol. 2006;8(11):1812–25.
103. Brennan MA, Cookson BT. Salmonella induces macrophage death by
caspase-1-dependent necrosis. Mol Microbiol. 2000;38(1):31–40.
104. Monack DM, Raupach B, Hromockyj AE, Falkow S. Salmonella typhimurium
invasion induces apoptosis in infected macrophages. Proc Natl Acad Sci U S
A. 1996;93(18):9833–8.
105. Hilbi H, Chen Y, Thirumalai K, Zychlinsky A. The interleukin 1beta-converting
enzyme, caspase 1, is activated during Shigella flexneri-induced apoptosis in
human monocyte-derived macrophages. Infect Immun.
1997;65(12):5165–70.
106. von Moltke J, Ayres JS, Kofoed EM, Chavarria-Smith J, Vance RE. Recognition
of bacteria by inflammasomes. Annu Rev Immunol. 2013;31:73–106.
107. Chae JJ, Cho YH, Lee GS, Cheng J, Liu PP, Feigenbaum L, et al. Gain-of-function
Pyrin mutations induce NLRP3 protein-independent interleukin-1beta
activation and severe autoinflammation in mice. Immunity. 2011;34(5):755–68.
108. Xu J, Jiang Y, Wang J, Shi X, Liu Q, Liu Z, et al. Macrophage endocytosis of
high-mobility group box 1 triggers pyroptosis. Cell Death Differ.
2014;21(8):1229–39.
109. Franklin BS, Bossaller L, De Nardo D, Ratter JM, Stutz A, Engels G, et al. The
adaptor ASC has extracellular and 'prionoid' activities that propagate
inflammation. Nat Immunol. 2014;15(8):727–37.
110. Delaleu N, Bickel M. Interleukin-1 beta and interleukin-18: regulation and
activity in local inflammation. Periodontol 2000. 2004;35:42–52.
111. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates
both Th1 and Th2 responses. Annu Rev Immunol. 2001;19:423–74.
Yang et al. Military Medical Research  (2015) 2:12 Page 11 of 12112. Gurcel L, Abrami L, Girardin S, Tschopp J, van der Goot FG. Caspase-1
activation of lipid metabolic pathways in response to bacterial pore-forming
toxins promotes cell survival. Cell. 2006;126(6):1135–45.
113. Wang S, Miura M, Jung Y, Zhu H, Gagliardini V, Shi L, et al. Identification and
characterization of Ich-3, a member of the interleukin-1beta converting
enzyme (ICE)/Ced-3 family and an upstream regulator of ICE. J Biol Chem.
1996;271(34):20580–7.
114. Wang S, Miura M, Jung YK, Zhu H, Li E, Yuan J. Murine caspase-11, an ICE-
interacting protease, is essential for the activation of ICE. Cell.
1998;92(4):501–9.
115. Kang SJ, Wang S, Hara H, Peterson EP, Namura S, Amin-Hanjani S, et al. Dual
role of caspase-11 in mediating activation of caspase-1 and caspase-3 under
pathological conditions. J Cell Biol. 2000;149(3):613–22.
116. Hagar JA, Powell DA, Aachoui Y, Ernst RK, Miao EA. Cytoplasmic LPS
activates caspase-11: implications in TLR4-independent endotoxic shock.
Science. 2013;341(6151):1250–3.
117. Kayagaki N, Wong MT, Stowe IB, Ramani SR, Gonzalez LC, Akashi-Takamura S,
et al. Noncanonical inflammasome activation by intracellular LPS independent
of TLR4. Science. 2013;341(6151):1246–9.
118. Lara-Tejero M, Sutterwala FS, Ogura Y, Grant EP, Bertin J, Coyle AJ, et al. Role
of the caspase-1 inflammasome in Salmonella typhimurium pathogenesis. J
Exp Med. 2006;203(6):1407–12.
119. Raupach B, Peuschel SK, Monack DM, Zychlinsky A. Caspase-1-mediated
activation of interleukin-1beta (IL-1beta) and IL-18 contributes to innate
immune defenses against Salmonella enterica serovar Typhimurium
infection. Infect Immun. 2006;74(8):4922–6.
120. Mariathasan S, Weiss DS, Dixit VM, Monack DM. Innate immunity against
Francisella tularensis is dependent on the ASC/caspase-1 axis. J Exp Med.
2005;202(8):1043–9.
121. Zamboni DS, Kobayashi KS, Kohlsdorf T, Ogura Y, Long EM, Vance RE, et al. The
Birc1e cytosolic pattern-recognition receptor contributes to the detection and
control of Legionella pneumophila infection. Nat Immunol.
2006;7(3):318–25.
122. Sansonetti PJ, Phalipon A, Arondel J, Thirumalai K, Banerjee S, Akira S, et al.
Caspase-1 activation of IL-1beta and IL-18 are essential for Shigella flexneri-
induced inflammation. Immunity. 2000;12(5):581–90.
123. Pedra JH, Sutterwala FS, Sukumaran B, Ogura Y, Qian F, Montgomery RR,
et al. ASC/PYCARD and caspase-1 regulate the IL-18/IFN-gamma axis during
Anaplasma phagocytophilum infection. J Immunol. 2007;179(7):4783–91.
124. Aachoui Y, Leaf IA, Hagar JA, Fontana MF, Campos CG, Zak DE, et al.
Caspase-11 protects against bacteria that escape the vacuole. Science.
2013;339(6122):975–8.
125. Ceballos-Olvera I, Sahoo M, Miller MA, Del Barrio L, Re F. Inflammasome-
dependent pyroptosis and IL-18 protect against Burkholderia pseudomallei
lung infection while IL-1beta is deleterious. PLoS Pathog.
2011;7(12):e1002452.
126. Tsuji NM, Tsutsui H, Seki E, Kuida K, Okamura H, Nakanishi K, et al. Roles of
caspase-1 in Listeria infection in mice. Int Immunol. 2004;16(2):335–43.
127. Simon A, van der Meer JW. Pathogenesis of familial periodic fever
syndromes or hereditary autoinflammatory syndromes. Am J Physiol Regul
Integr Comp Physiol. 2007;292(1):R86–98.
128. Frantz S, Ducharme A, Sawyer D, Rohde LE, Kobzik L, Fukazawa R, et al.
Targeted deletion of caspase-1 reduces early mortality and left ventricular
dilatation following myocardial infarction. J Mol Cell Cardiol.
2003;35(6):685–94.
129. Schielke GP, Yang GY, Shivers BD, Betz AL. Reduced ischemic brain injury in
interleukin-1 beta converting enzyme-deficient mice. J Cereb Blood Flow
Metab. 1998;18(2):180–5.
130. Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM, et al.
Inhibition of caspase-1 slows disease progression in a mouse model of
Huntington's disease. Nature. 1999;399(6733):263–7.
131. Siegmund B, Lehr HA, Fantuzzi G, Dinarello CA. IL-1 beta -converting
enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A.
2001;98(23):13249–54.
132. Li P, Allen H, Banerjee S, Franklin S, Herzog L, Johnston C, et al. Mice
deficient in IL-1 beta-converting enzyme are defective in production of
mature IL-1 beta and resistant to endotoxic shock. Cell. 1995;80(3):401–11.
133. Willingham SB, Bergstralh DT, O'Connor W, Morrison AC, Taxman DJ,
Duncan JA, et al. Microbial pathogen-induced necrotic cell death mediated
by the inflammasome components CIAS1/cryopyrin/NLRP3 and ASC. Cell
Host Microbe. 2007;2(3):147–59.134. Duncan JA, Gao X, Huang MT, O'Connor BP, Thomas CE, Willingham SB,
et al. Neisseria gonorrhoeae activates the proteinase cathepsin B to mediate
the signaling activities of the NLRP3 and ASC-containing inflammasome.
J Immunol. 2009;182(10):6460–9.
135. Zhao YO, Khaminets A, Hunn JP, Howard JC. Disruption of the Toxoplasma
gondii parasitophorous vacuole by IFNgamma-inducible immunity-related
GTPases (IRG proteins) triggers necrotic cell death. PLoS Pathog.
2009;5(2):e1000288.
136. Averette KM, Pratt MR, Yang Y, Bassilian S, Whitelegge JP, Loo JA, et al.
Anthrax lethal toxin induced lysosomal membrane permeabilization and
cytosolic cathepsin release is Nlrp1b/Nalp1b-dependent. Plos One.
2009;4(11):e7913.
137. Holzinger D, Gieldon L, Mysore V, Nippe N, Taxman DJ, Duncan JA, et al.
Staphylococcus aureus Panton-Valentine leukocidin induces an inflammatory
response in human phagocytes via the NLRP3 inflammasome. J Leukoc Biol.
2012;92(5):1069–81.
138. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al.
Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532–5.
139. Brinkmann V, Zychlinsky A. Beneficial suicide: why neutrophils die to make
NETs. Nat Rev Microbiol. 2007;5(8):577–82.
140. Papayannopoulos V, Zychlinsky A. NETs: a new strategy for using old
weapons. Trends Immunol. 2009;30(11):513–21.
141. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, et al. Novel
cell death program leads to neutrophil extracellular traps. J Cell Biol.
2007;176(2):231–41.
142. Yipp BG, Kubes P. NETosis: how vital is it? Blood. 2013;122(16):2784–94.
143. Remijsen Q, Kuijpers TW, Wirawan E, Lippens S, Vandenabeele P, Vanden
Berghe T. Dying for a cause: NETosis, mechanisms behind an antimicrobial
cell death modality. Cell Death Differ. 2011;18(4):581–8.
144. Wartha F, Henriques-Normark B. ETosis: a novel cell death pathway. Sci Signal.
2008;1(21):e25.
145. Bianchi M, Hakkim A, Brinkmann V, Siler U, Seger RA, Zychlinsky A, et al.
Restoration of NET formation by gene therapy in CGD controls aspergillosis.
Blood. 2009;114(13):2619–22.
146. Pilsczek FH, Salina D, Poon KK, Fahey C, Yipp BG, Sibley CD, et al. A novel
mechanism of rapid nuclear neutrophil extracellular trap formation in
response to Staphylococcus aureus. J Immunol.
2010;185(12):7413–25.
147. Buchanan JT, Simpson AJ, Aziz RK, Liu GY, Kristian SA, Kotb M, et al. DNase
expression allows the pathogen group A Streptococcus to escape killing in
neutrophil extracellular traps. Curr Biol. 2006;16(4):396–400.
148. Urban CF, Reichard U, Brinkmann V, Zychlinsky A. Neutrophil extracellular
traps capture and kill Candida albicans yeast and hyphal forms. Cell
Microbiol. 2006;8(4):668–76.
149. Jaillon S, Peri G, Delneste Y, Fremaux I, Doni A, Moalli F, et al. The humoral
pattern recognition receptor PTX3 is stored in neutrophil granules and
localizes in extracellular traps. J Exp Med. 2007;204(4):793–804.
150. Mulcahy H, Charron-Mazenod L, Lewenza S. Extracellular DNA chelates
cations and induces antibiotic resistance in Pseudomonas aeruginosa
biofilms. PLoS Pathog. 2008;4(11):e1000213.
151. Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase
and myeloperoxidase regulate the formation of neutrophil extracellular
traps. J Cell Biol. 2010;191(3):677–91.
152. Saitoh T, Komano J, Saitoh Y, Misawa T, Takahama M, Kozaki T, et al. Neutrophil
extracellular traps mediate a host defense response to human
immunodeficiency virus-1. Cell Host Microbe. 2012;12(1):109–16.
153. Wardini AB, Guimaraes-Costa AB, Nascimento MT, Nadaes NR, Danelli MG,
Mazur C, et al. Characterization of neutrophil extracellular traps in cats naturally
infected with feline leukemia virus. J Gen Virol. 2010;91(Pt 1):259–64.
154. Ng HH, Narasaraju T, Phoon MC, Sim MK, Seet JE, Chow VT. Doxycycline
treatment attenuates acute lung injury in mice infected with virulent
influenza H3N2 virus: involvement of matrix metalloproteinases. Exp Mol
Pathol. 2012;92(3):287–95.
155. Narasaraju T, Yang E, Samy RP, Ng HH, Poh WP, Liew AA, et al. Excessive
neutrophils and neutrophil extracellular traps contribute to acute lung
injury of influenza pneumonitis. Am J Pathol. 2011;179(1):199–210.
156. Barletta KE, Cagnina RE, Burdick MD, Linden J, Mehrad B. Adenosine A(2B)
receptor deficiency promotes host defenses against gram-negative bacterial
pneumonia. Am J Respir Crit Care Med. 2012;186(10):1044–50.
157. Douda DN, Jackson R, Grasemann H, Palaniyar N. Innate immune collectin
surfactant protein D simultaneously binds both neutrophil extracellular traps
Yang et al. Military Medical Research  (2015) 2:12 Page 12 of 12and carbohydrate ligands and promotes bacterial trapping. J Immunol.
2011;187(4):1856–65.
158. Li P, Li M, Lindberg MR, Kennett MJ, Xiong N, Wang Y. PAD4 is essential for
antibacterial innate immunity mediated by neutrophil extracellular traps.
J Exp Med. 2010;207(9):1853–62.
159. Bruns S, Kniemeyer O, Hasenberg M, Aimanianda V, Nietzsche S, Thywissen
A, et al. Production of extracellular traps against Aspergillus fumigatus
in vitro and in infected lung tissue is dependent on invading neutrophils
and influenced by hydrophobin RodA. PLoS Pathog.
2010;6(4):e1000873.
160. Hosogi S, Iwasaki Y, Yamada T, Komatani-Tamiya N, Hiramatsu A, Kohno Y,
et al. Effect of inducible nitric oxide synthase on apoptosis in Candida-
induced acute lung injury. Biomed Res. 2008;29(5):257–66.
161. Thomas GM, Carbo C, Curtis BR, Martinod K, Mazo IB, Schatzberg D, et al.
Extracellular DNA traps are associated with the pathogenesis of TRALI in
humans and mice. Blood. 2012;119(26):6335–43.
162. Caudrillier A, Kessenbrock K, Gilliss BM, Nguyen JX, Marques MB, Monestier
M, et al. Platelets induce neutrophil extracellular traps in transfusion-related
acute lung injury. J Clin Invest. 2012;122(7):2661–71.
163. Roghanian A, Sallenave JM. Neutrophil elastase (NE) and NE inhibitors:
canonical and noncanonical functions in lung chronic inflammatory
diseases (cystic fibrosis and chronic obstructive pulmonary disease). J
Aerosol Med Pulm Drug Deliv. 2008;21(1):125–44.
164. Gupta AK, Joshi MB, Philippova M, Erne P, Hasler P, Hahn S, et al. Activated
endothelial cells induce neutrophil extracellular traps and are susceptible to
NETosis-mediated cell death. FEBS Lett. 2010;584(14):3193–7.
165. Eskelinen EL, Saftig P. Autophagy: a lysosomal degradation pathway with a
central role in health and disease. Biochim Biophys Acta.
2009;1793(4):664–73.
166. Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green-
Thompson ZW, et al. Regulation of mammalian autophagy in physiology
and pathophysiology. Physiol Rev. 2010;90(4):1383–435.
167. Shimizu S, Kanaseki T, Mizushima N, Mizuta T, Arakawa-Kobayashi S,
Thompson CB, et al. Role of Bcl-2 family proteins in a non-apoptotic
programmed cell death dependent on autophagy genes. Nat Cell Biol.
2004;6(12):1221–8.
168. Kroemer G, Levine B. Autophagic cell death: the story of a misnomer. Nat
Rev Mol Cell Biol. 2008;9(12):1004–10.
169. Shen HM, Codogno P. Autophagic cell death: Loch Ness monster or
endangered species? Autophagy. 2011;7(5):457–65.
170. Mizushima N, Yoshimori T, Ohsumi Y. The role of Atg proteins in
autophagosome formation. Annu Rev Cell Dev Biol. 2011;27:107–32.
171. Mizushima N. The role of the Atg1/ULK1 complex in autophagy regulation.
Curr Opin Cell Biol. 2010;22(2):132–9.
172. Lee JW, Park S, Takahashi Y, Wang HG. The association of AMPK with ULK1
regulates autophagy. Plos One. 2010;5(11):e15394.
173. Filimonenko M, Isakson P, Finley KD, Anderson M, Jeong H, Melia TJ, et al.
The selective macroautophagic degradation of aggregated proteins requires
the PI3P-binding protein Alfy. Mol Cell. 2010;38(2):265–79.
174. Simonsen A, Birkeland HC, Gillooly DJ, Mizushima N, Kuma A, Yoshimori T,
et al. Alfy, a novel FYVE-domain-containing protein associated with protein
granules and autophagic membranes. J Cell Sci. 2004;117(Pt 18):4239–51.
175. Itakura E, Kishi-Itakura C, Mizushima N. The hairpin-type tail-anchored SNARE
syntaxin 17 targets to autophagosomes for fusion with endosomes/lysosomes.
Cell. 2012;151(6):1256–69.
176. Furuta N, Fujita N, Noda T, Yoshimori T, Amano A. Combinational soluble
N-ethylmaleimide-sensitive factor attachment protein receptor proteins
VAMP8 and Vti1b mediate fusion of antimicrobial and canonical autophagosomes
with lysosomes. Mol Biol Cell. 2010;21(6):1001–10.
177. Xu Y, Jagannath C, Liu XD, Sharafkhaneh A, Kolodziejska KE, Eissa NT. Toll-
like receptor 4 is a sensor for autophagy associated with innate immunity.
Immunity. 2007;27(1):135–44.
178. Delgado MA, Elmaoued RA, Davis AS, Kyei G, Deretic V. Toll-like receptors
control autophagy. EMBO J. 2008;27(7):1110–21.
179. Travassos LH, Carneiro LA, Ramjeet M, Hussey S, Kim YG, Magalhaes JG,
et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the
plasma membrane at the site of bacterial entry. Nat Immunol.
2010;11(1):55–62.
180. Cooney R, Baker J, Brain O, Danis B, Pichulik T, Allan P, et al. NOD2
stimulation induces autophagy in dendritic cells influencing bacterial
handling and antigen presentation. Nat Med. 2010;16(1):90–7.181. Harris J, Hartman M, Roche C, Zeng SG, O'Shea A, Sharp FA, et al. Autophagy
controls IL-1beta secretion by targeting pro-IL-1beta for degradation. J Biol
Chem. 2011;286(11):9587–97.
182. Shi CS, Shenderov K, Huang NN, Kabat J, Abu-Asab M, Fitzgerald KA, et al.
Activation of autophagy by inflammatory signals limits IL-1beta production
by targeting ubiquitinated inflammasomes for destruction. Nat Immunol.
2012;13(3):255–63.
183. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V.
Autophagy is a defense mechanism inhibiting BCG and Mycobacterium
tuberculosis survival in infected macrophages. Cell. 2004;119(6):753–66.
184. Harris J, De Haro SA, Master SS, Keane J, Roberts EA, Delgado M, et al. T
helper 2 cytokines inhibit autophagic control of intracellular Mycobacterium
tuberculosis. Immunity. 2007;27(3):505–17.
185. Singh SB, Ornatowski W, Vergne I, Naylor J, Delgado M, Roberts E, et al. Human
IRGM regulates autophagy and cell-autonomous immunity functions through
mitochondria. Nat Cell Biol. 2010;12(12):1154–65.
186. Schmid D, Munz C. Innate and adaptive immunity through autophagy.
Immunity. 2007;27(1):11–21.
187. Rubinsztein DC, Codogno P, Levine B. Autophagy modulation as a potential
therapeutic target for diverse diseases. Nat Rev Drug Discov. 2012;11(9):709–30.
188. Johansen T, Lamark T. Selective autophagy mediated by autophagic
adapter proteins. Autophagy. 2011;7(3):279–96.
189. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, et al.
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing
the number of confirmed associations to 47. Nat Genet. 2011;43(3):246–52.
190. Craddock N, Hurles ME, Cardin N, Pearson RD, Plagnol V, Robson S, et al.
Genome-wide association study of CNVs in 16,000 cases of eight common
diseases and 3,000 shared controls. Nature. 2010;464(7289):713–20.
191. Henckaerts L, Cleynen I, Brinar M, John JM, Van Steen K, Rutgeerts P, et al.
Genetic variation in the autophagy gene ULK1 and risk of Crohn's disease.
Inflamm Bowel Dis. 2011;17(6):1392–7.
192. Ferwerda G, Kramer M, de Jong D, Piccini A, Joosten LA, Devesaginer I, et al.
Engagement of NOD2 has a dual effect on proIL-1beta mRNA transcription
and secretion of bioactive IL-1beta. Eur J Immunol. 2008;38(1):184–91.
193. Plantinga TS, Crisan TO, Oosting M, van de Veerdonk FL, de Jong DJ, Philpott DJ,
et al. Crohn's disease-associated ATG16L1 polymorphism modulates pro-
inflammatory cytokine responses selectively upon activation of NOD2. Gut.
2011;60(9):1229–35.
194. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC, et al.
Autophagy proteins regulate innate immune responses by inhibiting the
release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat
Immunol. 2011;12(3):222–30.
195. Wen Z, Fan L, Li Y, Zou Z, Scott MJ, Xiao G, et al. Neutrophils counteract
autophagy-mediated anti-inflammatory mechanisms in alveolar macrophage:
role in posthemorrhagic shock acute lung inflammation. J Immunol.
2014;193(9):4623–33.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
